Does systemic HRT fix vaginal dryness for everyone?
Does systemic HRT fix vaginal dryness for everyone? Not always. Many feel better on HRT, but genitourinary syndrome of menopause (GSM) often needs local therapy (vaginal oestrogen or DHEA) alongside moisturisers and a suitable lubricant. If dryness, dyspareunia or urinary urgency persist on well-dosed HRT, adding local treatment is common. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Does systemic HRT fix vaginal dryness for everyone? Not for everyone. Systemic hormone replacement therapy (HRT)—tablets, patches or gels—can help vasomotor symptoms (hot flushes, sleep, mood) and may improve vaginal comfort for some. But the vulvo-vaginal tissues and the urethral/bladder entrance often need local support because genitourinary syndrome of menopause (GSM, historically “vaginal atrophy”) reflects very low oestrogen within those tissues specifically. That’s why many people on well-dosed HRT still have dryness, burning, recurrent micro-tears, dyspareunia, or urinary urgency/frequency until local vaginal oestrogen or vaginal DHEA is added.
Why systemic HRT isn’t always enough. With menopause, oestrogen falls; the vaginal epithelium thins, glycogen (fuel for lactobacilli) drops, and pH rises. These local changes increase friction sensitivity and reduce arousal lubrication. Systemic HRT raises circulating hormones but does not always deliver sufficient concentrations to the vaginal epithelium to reverse GSM on its own—especially at low systemic doses used for safety/tolerability. Local therapies act directly where they’re needed, maturing the lining, lowering pH, restoring elasticity and moisture more reliably.
What a stepped plan looks like. First build foundations: gentle vulval care (lukewarm water; bland emollient as a soap substitute externally; avoid fragranced washes/wipes); schedule a vaginal moisturiser (many prefer hyaluronic-acid gels) several times weekly; and use a compatible personal lubricant for higher-friction moments—water-based (versatile, condom-friendly), silicone-based (long-lasting glide for dyspareunia), or oil-based (rich feel but may degrade latex condoms and some toys). If dryness persists—whether you use systemic HRT or not—add a local option: vaginal oestrogen (cream, tablet/pessary or estradiol ring) or vaginal DHEA. Many notice early relief in 2–4 weeks and fuller comfort by 8–12 weeks.
Common scenarios on HRT. 1) Flushes improve, dryness persists: add local therapy while continuing HRT. 2) Good days then “sudden dryness” flares: check irritants (new wash product, tight kit, long cycling) and consistency with moisturiser; consider local oestrogen/DHEA if flares continue. 3) Dyspareunia focused at the entrance: even with HRT, a fingertip of local oestrogen cream at the vestibule (as advised) can target micro-tears; silicone-based lubricant may help glide. 4) Urinary frequency/urgency: GSM-related symptoms often respond to local oestrogen at the urethral/bladder neck region over weeks.
When to review technique and placement. If you’ve added local therapy but the entrance still burns, ensure product is reaching the tender spot (posterior fourchette/vestibule) and not just high in the vagina. For pessaries/tablets, some add a tiny external smear of non-hormonal moisturiser on alternate nights. If pain has led to pelvic floor guarding, adding pelvic health physiotherapy (and, where needed, psychosexual therapy) can reduce the “sharp” entrance pain even as tissue hydration improves.
Clinic navigation. For plain-English overviews of what treatment involves and how we sequence steps, see our internal guides. If you’re weighing timelines and budgets, we can also outline typical review points and maintenance once comfortable. Educational only. Results vary. Not a cure.
Clinical Context
Who may still need local therapy despite HRT? People with persistent dryness, stinging with urine on delicate skin, superficial fissures, dyspareunia, or GSM-linked urinary urgency/frequency. Those after surgical menopause, on lower HRT doses for tolerance, or with long-standing GSM often improve only when a local option is added.
Alternatives and next steps. If you prefer to avoid local hormones, maximise non-hormonal care: scheduled moisturiser (often with hyaluronic acid), a compatible lubricant, friction reduction, and gentle external care. If symptoms remain intrusive, discuss vaginal oestrogen or vaginal DHEA. Energy-based devices (vaginal laser/radiofrequency) and regenerative injectables (e.g., PRP or polynucleotides) are not first-line; consider cautiously after guideline-led options. Plan a 6–12-week review to adjust to the lowest effective maintenance.
Evidence-Based Approaches
Practical NHS overviews cover symptoms and self-care for vaginal dryness and when to seek help for painful sex (dyspareunia). The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life, with or without systemic HRT; many people on HRT still need local therapy for GSM.
Systematic reviews in the Cochrane Library show that local oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings. Prescribing-level UK product information and cautions are set out in the British National Formulary (BNF). Peer-reviewed overviews on PubMed describe GSM mechanisms (thinner epithelium, raised pH, lactobacilli loss) and explain why local therapies are often required alongside or instead of systemic HRT for urogenital symptoms.
Applying the evidence: treat GSM step-wise: non-hormonal foundations → add local therapy if symptoms persist (whether or not you use systemic HRT) → review placement/technique and pelvic floor factors → maintain the minimum effective regimen, with periodic review. ® belongs to its owner.